Genitourinary Cancer | Norton Healthcare

Indication: Genitourinary Cancer

An Expanded/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) and Metastatic Castrate Resistant Prostate Cancer (mCRPC) who Failed Either Abiraterone or Enzalutamide

Prostate Cancer

Sub-indication: Progressive disease despite hormonal treatment with abiraterone or enzalutamide, but not both. One line of chemotherapy is eligible

Line of Therapy: 2nd Line

Drug Study

Principal Investigator: Chandler Park, M.D.
Norton Cancer Institute

Sponsor: Suzhou Kintor Pharmaceuticals, Inc.

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.